Add Yahoo as a preferred source to see more of our stories on Google. Moderna and MSD's mRNA cancer vaccine A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD ...
The combination of intismeran autogene and Keytruda reduced recurrence or death risk by 49% in high-risk melanoma patients over five years. The study involved 157 patients with stage 3/4 melanoma who ...
IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The combination therapy showed a significant PFS benefit in PD-L1–negative patients, with ...
A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...
LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...
Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results